Plasma-derived therapies and the fight against COVID-19

5 March 2021

Patrick Delavault, executive vice president, scientific & medical affairs, LFB Biopharmaceuticals, provides an Expert View on how the pandemic has led to a focus on an important medicinal option for patients.

In 2020, we saw several leading biopharmaceutical companies combine forces in the search for therapeutic solutions to fight the current global pandemic. Little may be known about plasma-derived therapies in the world at large, but the COVID-19 pandemic has shone a light on this form of treatment and highlighted its wider uses in everyday medicine.

Plasma-derived medicinal products and recombinant proteins are typically used to treat rare, serious, genetic, and — in many cases — life-threatening diseases caused by defective immune systems or by missing or non-functioning proteins typically found in blood plasma. These include autoimmune disorders and inherited disorders of hemostasis. Plasma-derived therapies also play an important role in emergency medicine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK